| Patient | Sir John Franklin |
|---|---|
| Date of birth | 1786-04-16 |
| Identifiers | MRN HR-EX005-SYN-TD; SSN (made up) 000-05-3328 |
| Document date | 1845-01-27 |
| Author | Cordelia Ashby-Nwankwo, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two-week review of home blood pressure readings, seen the same day by wilderness and expedition medicine. [S]
Sir John returns with a week of home readings, taken morning and evening with a validated upper-arm monitor and a large cuff: the average of 28 readings is 144/90, with no reading below 132/84. He has cut his wine to one glass with dinner and his salt, and walks every day. He has no headaches, chest pain, breathlessness, palpitations or ankle swelling. He brought no urine sample to the intake visit and has not yet given one. The tuberculosis blood test drawn at intake is negative. He is seen this afternoon by Dr. Okafor-Lindqvist of wilderness and expedition medicine. [S]
| Element | Detail |
|---|---|
| Home readings | Seven-day average 144/90 mmHg (28 readings) |
| Office reading | 148/92 mmHg |
| Symptoms | None |
| Lifestyle | One glass of wine with dinner; less salt; daily walks |
| Tuberculosis blood test | Negative |
| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No chest pain, palpitations or ankle swelling |
| Respiratory | Negative | No breathlessness |
| Neurological | Negative | No headache or visual change |
| Psychiatric | Negative | Mood good; looking forward to the command |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Amlodipine 5 mg oral tablet once daily | One tablet by mouth every morning | Oral route | 1845-01-27 | active | S |
| Vitamin D3 (cholecalciferol) 25 micrograms (1,000 units) oral tablet once daily, continued through the polar winters | One tablet by mouth daily | Oral route | 1845-01-27 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1845-01-27 | Body height | 170 | cm | S |
| 1845-01-27 | Body weight | 90.4 | kg | S |
| 1845-01-27 | Body mass index (BMI) [Ratio] | 31.3 | kg/m2 | S |
| 1845-01-27 | Systolic blood pressure | 148 | mm[Hg] | S |
| 1845-01-27 | Diastolic blood pressure | 92 | mm[Hg] | S |
| 1845-01-27 | Heart rate | 76 | /min | S |
| 1845-01-27 | Respiratory rate | 14 | /min | S |
| 1845-01-27 | Body temperature | 36.6 | Cel | S |
| 1845-01-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
Vital signs recorded on 1845-01-27; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 148/92, pulse 76; weight 90.4 kg, BMI 31.3; waist 106 cm |
| Eyes | Fundi: no arteriovenous nicking, hemorrhages or exudates |
| Cardiovascular | Regular rhythm; no murmur or gallop; no carotid or abdominal bruit; foot pulses present; no edema |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| High blood pressure found at the pre-expedition medical (152/94 mmHg, average of two readings), without a prior diagnosis; home readings for one week ordered to confirm | resolved | confirmed | R03.0 | S — Synthetic presenting finding at a pre-expedition fitness assessment, anchored to the documented doubts about his fitness; superseded when home readings confirmed hypertension. |
| Essential hypertension, stage 2 by home readings (one-week average 144/90 mmHg), without target-organ damage; synthetic | active | confirmed | I10 | S — Synthetic modern diagnosis confirmed by home monitoring at the consultation; no blood pressure from his lifetime is recorded. |
| Obesity, class 1 (BMI 31.4 at intake), with a waist of 106 cm; he sets his own goals for activity and food | active | confirmed | E66.811 | S — Synthetic modern finding anchored to the documented description of his build as portly; no weight from his lifetime is recorded. |
| Medical preparation for a multi-year Arctic expedition beyond the reach of hospital care: fitness, cold injury, nutrition and food safety, vaccinations, dental care, mental health in isolation, a medical kit and an evacuation plan | active | confirmed | Z71.84 | S — Synthetic travel-health problem anchored to the documented expedition. |
| Bilateral high-frequency sensorineural hearing loss from noise, mild; trouble hearing in noisy rooms | active | confirmed | H83.3X3 | S — Synthetic modern coding of the documented mild hearing loss from naval gunfire; the audiogram is synthetic. |
| Vitamin D insufficiency in midwinter (25-hydroxyvitamin D 22 ng/mL), with years of polar darkness ahead | active | confirmed | E55.9 | S — Synthetic laboratory finding at intake. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Office blood pressure (seated, five minutes' rest, large cuff, average of two readings) | Every visit | Completed today | 148/92 mmHg |
| Self-management | Home blood pressure monitoring | At diagnosis and two to four weeks after each treatment change, then weekly | Completed today | Seven-day average 144/90 mmHg confirms stage 2 hypertension; repeat a week before the next visit |
| Examination | Weight, BMI and waist | Every visit | Completed today | 90.4 kg, BMI 31.3, waist 106 cm |
| Examination | Cardiac auscultation | Every visit | Completed today | No murmur or gallop |
| Examination | Fundoscopic examination | Yearly | Completed today | No hypertensive retinopathy |
| Laboratory | Basic metabolic panel, potassium and eGFR | Yearly (every six months only on a diuretic or renin-angiotensin blocker) | Up to date | Normal at intake: sodium 140, potassium 4.2, creatinine 0.98 mg/dL, eGFR 88 |
| Laboratory | Lipid panel | Yearly | Up to date | At intake: total cholesterol 188, HDL 52, LDL 112, triglycerides 120 mg/dL |
| Laboratory | HbA1c or fasting glucose | Yearly | Up to date | HbA1c 5.6% at intake |
| Laboratory | Urine albumin-to-creatinine ratio | At diagnosis, then yearly | Deferred | The urine sample planned at intake was not collected, and none was given today. Without it, early kidney damage cannot be excluded, but creatinine, eGFR and the fundi are normal, so no harm is likely in the next few weeks. Corrective action: a urine cup given today and a standing order for the next visit |
| Laboratory | TSH | At diagnosis | Up to date | 1.9 mIU/L at intake |
| Imaging | 12-lead ECG | At diagnosis | Up to date | Normal at intake; no left ventricular hypertrophy |
| Imaging | Echocardiogram | At diagnosis of stage 2 hypertension or suspected left ventricular hypertrophy | Ordered | Booked before the four-week review |
| Imaging | Renal ultrasound or renal artery imaging | Only for resistant hypertension or a suspected secondary cause | Not indicated | No features of a secondary cause; potassium normal |
| Examination | Ankle-brachial index | Every two to three years from 65 or with a smoking history | Not indicated | Age 58 and never smoked; foot pulses present |
| Survey | Cardiovascular risk (PREVENT and Pooled Cohort Equations) | Yearly | Completed today | PREVENT about 6 percent; Pooled Cohort Equations about 8 percent; statin declined for now |
| Survey | PHQ-9 depression screen | Yearly | Up to date | PHQ-9 3 at intake, item 9 scored 0 |
| Medication safety | Amlodipine safety: ankle swelling, dizziness, flushing | When started and at each visit | Completed today | Started today; told to report ankle swelling or dizziness |
| Referral | Wilderness and expedition medicine consultation | Before clearance for remote duty | Completed today | Seen by Dr. Okafor-Lindqvist today |
| Examination | Exercise treadmill test before strenuous remote work | Before clearance | Ordered | Booked in four weeks |
| Self-management | Nutrition and food safety for the expedition (vitamin C and D, rations, cans, lead, botulism) | Before departure | Completed today | Vitamin D3 started; vitamin C plan and food-safety advice given |
Goal progress:
Guideline basis: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, hypertension and hyperlipidemia monographs (2026); Wilderness Medical Society Clinical Practice Guidelines for the Prevention and Treatment of Frostbite: 2024 Update (2024); Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021 (2021); Recommendations for medical management of adult lead exposure (2007); Weight Loss to Prevent Obesity-Related Morbidity and Mortality in Adults: Behavioral Interventions (2018); Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication (2022)
Follow-up: Echocardiogram and urine sample before the four-week review. Home readings for a week before then. Call for chest pain, breathlessness, fainting or ankle swelling. Next scheduled visit 1845-02-24: four-week review after starting amlodipine: blood pressure, side effects, echocardiogram and urine albumin. [S]